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 Abstract 
Depression is a major co-morbid condition with epilepsy, and has been found to 
be the single largest determinant of health-related quality of life in patients with epilepsy, 
even greater than seizure frequency and severity.  Several studies have looked at the 
changes in symptoms of depression in patient treated with Vagus Nerve Stimulation for 
epilepsy.  However, these studies have had some major limitations, including that they 
relied on scales designed to measure severity of depression in a population of clinically 
depressed patients instead of a scale that measures depressive symptoms in a community 
population, and that they measured changes in symptoms after only six months of VNS, 
even though research suggest that the benefit of VNS, in terms of reducing both seizure 
frequency and depression, strengths over a longer time period than six months. 
Our study aims to demonstrate an improvement in depression symptoms 
measured by the Center for Epidemiologic Study of Depression scale (CES-D) after one 
year or more of VNS.  Methods: Seven adults with epilepsy treated with VNS were asked 
to fill out two sets of scales, one in reference to how they felt the month prior to VNS 
implantation and the other for how they felt after at least one year of VNS.  Results: 
Scores on the CES-D improved from an average of 24.3 before VNS to an average of 
19.8 at least one year after insertion, however, this change was not statistically significant 
(p=0.327).  Overall functioning, as measured by the Darthmouth COOP scale, improved 
from an average score of 29 before VNS to an average of 2.2 at least one year after VNS 
(lower score indicates higher functioning), which was statistically significant (p=0.012).  
Seizure severity, as determined by a continuous 0-10 scale, improved from an average of 
6.64 prior to VNS insertion to 2.98 after at least one year of VNS, which approached 
statistical significance (p=0.06).  Conclusion: Our results suggest that there is an 
improvement in symptoms of depression and overall functioning in patient with epilepsy 
after one year or more of VNS, and that the change in functioning is directly related to a 
reduction in seizure severity.   
 
Introduction 
Vagus Nerve Stimulation and Epilepsy 
 In 1985, Dr. Jacob Zabara first proposed Vagus Nerve Stimulation, or VNS, as a 
potential treatment for seizures due to its potential ability to desynchronize 
electrocerebral activities.1    Observations from animal studies indicated that VNS can 
affect seizure activity and could be a potential treatment for epilepsy in humans.   
 Two randomized clinical trials were conducted in the 1990’s by the Vagus Nerve 
Stimulation Group and Handforth et al. in patients with localized epilepsy to evaluate 
VNS as a treatment for epilepsy.  These two studies used an “active placebo” design with 
low and high intensity stimulation to measure the percent change in seizure frequency 
compared with baseline seizure rates.2   The Vagus Nerve Stimulation Group analyzed 
114 patients and found that there was a 24.5% reduction in seizures in the high 
stimulation group vs. a 6.1% reduction in the low.3  The Handforth et al. study analyzed 
196 patients and found a 28% reduction in seizure frequency in the high stimulation 
group and a 15% reduction in the low stimulation group. 2  These results along with a long 
term follow up study by DeGiorgio et. al demonstrated the efficacy of VNS in treatment 
for epilepsy, and proved that this efficacy was maintained and actually increased over 
time.   
 On the basis of these findings VNS was approved by the FDA in 1997 “for use as 
an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 
12 years of age with partial onset of seizures which are refractory to antiepileptic 
medications.”4  Despite its approval by the FDA the exact mechanisms of action of VNS 
is still under investigation.  The current putative mechanisms for VNS in epilepsy are that 
the antiseizure effects are mediated through: 1) increased synaptic activities of the 
thalamus and its projections leading to increased arousal and decreased synchrony of 
activities in the cortex which may influence the generation of generalized seizures and 
secondary generalization of focal seizures;  2) increased activity in the insula, 
hypothalamus and autonomic system; 3) decreased synaptic activity in the amygdala, 
hippocampus and limbic system; 4) increase in norepinephrine and perhaps serotonin 
exerting inhibitory influences on postsynaptic neurons.5,   6   
 VNS is currently used as one of three treatments for pharmaco-resistant seizures 
or for those patients who have unacceptable side effects for anti-epileptic drugs.7  VNS 
has been shown to be efficacious in short term treatment of epilepsy, and in the longer 
term maintenance of seizure reduction.8  The antiseizure effects of VNS also appear to 
increase with time, beginning with a 34% reduction after 3 months and increasing to a 
45% reduction after 12 months, with 20% of patients having a seizure frequency 
reduction of over 75%.9, , ,10 11 12  The incidence of adverse events with VNS is very low, 
and complications of surgery to place the VNS device such as wound infection or vocal 
chord paralysis occurs in only about 0.1% of cases.  VNS has an advantage over most 
AEDs in that its efficacy does not depend on patient compliance, and has emerged as an 
important adjunctive therapy for patients with refractory seizures.13
 
VNS for the Treatment of Major Depression
 With the increased use of VNS for refractory depression, patients began to report 
improvements in mood associated with the use of VNS.  These self-reports, along with 
the history of successful use of many other anti-epileptic therapies for the treatment of 
psychiatric disorders, created an impetus to investigate the use of VNS for treatment of 
mood disorders.  In 2000, Rush et al. published the first report in of VNS for use in adult 
outpatients with severe, treatment-resistant major depressive episodes.14   The study 
demonstrated that the positive treatment response rate was sustained starting at 40% at 3 
months and rising to 46% at 12 months.  Also of significance, three non-responders after 
3 months (characterized by less than 50% reduction in depression symptoms) became 
responders at the 12 month follow up, demonstrating that VNS effects on depression 
improve with time.15  
A study by George et al. subsequently compared the use of VNS and usual 
therapies for treatment-resistant depression and found that VNS was associated with 
greater antidepressant benefits over 12 months than typical treatment.16   The use of trial 
periods of 12 months in the above two studies is important, as other studies have failed to 
show evidence of short-term efficacy of VNS for treatment-resistant depression.  For 
example, one randomized, controlled trial comparing adjunctive VNS with sham 
treatment in 235 outpatients with non-psychotic major depressive disorder found no 
significant difference in response rates to VNS in the treatment vs. sham group after 10 
weeks.  Such studies suggest that a longer term treatment period is necessary to produce 
results with VNS.17
 In 2005, the results of studies such as those above prompted the FDA to approve 
VNS “for the adjunctive long-term treatment of chronic or recurrent depression for 
patients 18 years of age or older who are experiencing a major depressive episode and 
have not had an adequate response to four or more adequate antidepressant treatments.”18
 
Depression and Epilepsy 
 Epilepsy affects 6 to 7 people per 1,000 in the United States, with 40 to 50 new 
cases developing per 100,000 each year.19  Depression is highly prevalent in this 
population and is the most frequent co-morbid psychiatric disorder in patients with 
epilepsy.20,21  Overall, the rate of depression in patients with epilepsy is significantly 
higher than that of the general population; it is also higher than rates of depression in 
patients with other chronic diseases such as diabetes or asthma.22,23 The lifetime 
prevalence of depression in patients with epilepsy is estimated to be between 6% and 
30%, and up to 50% in patients followed in tertiary care centers.20  In patients with 
medically intractable, or only partially controlled epilepsy, rates of depression range from 
20% to 55%, while in patients with controlled epilepsy, rates range from 3% to 9%.24,        25
While the increased rate of depression in those with intractable epilepsy suggests 
a direct association between seizure frequency and severity with depressive symptoms, 
the relationship is actually more complex.  In fact, some patients have noted a decrease in 
seizure frequency prior to onset of depressive episodes.26  Furthermore, studies 
examining mood improvement in patients with epilepsy treated with VNS, have found no 
direct association between seizure reduction and mood improvement.27  Further 
complicating the issue is the concept of “forced normalization”, which suggests 
eliminating/ suppressing seizure may actually prompt psychiatric disorders, such as 
depression.  This concept is based on the idea that seizures produce alterations in brain 
chemistry that reduce/prevent depression. It is further supported by the efficacy of 
electroconvulsive therapy, in which seizures are induced in non-epileptic patients for the 
treatment of depression.  “Forced normalization” has been reported to occur in patients 
whose seizures have been suppressed with VNS, anti-epileptic drugs, and epilepsy 
surgery.28
   Although it is unclear exactly how seizure frequency and severity contribute to 
the increased rate of depression in patients with epilepsy, there are many factors which 
have been suggested to play a role.  The most common include: psychosocial factors, side 
effects of anti-epileptic drugs (AEDs), and a common pathogenic mechanism for epilepsy 
and depression.  Psychosocial factors experienced as a direct result of having epilepsy 
such as perceived stigma, fear of seizures, discrimination, joblessness, lack of social 
support, and lifestyle changes imposed by increased seizure severity/frequency (giving up 
driving privileges, changing jobs, etc.), have all been theorized to contribute to 
depression.29,30  Furthermore, many of the drugs used to treat epilepsy are known to have 
negative effects on mood.  Phenobarbital has been reported to cause depressive disorder, 
while primidone, tigabine, vigabatrin, felbamate, and topiramate can frequently cause 
symptoms of depression.20,31
The impact of depression in the epileptic population is substantial.  People with 
epilepsy are four times more likely to be hospitalized for depression than those without 
epilepsy32 and the risk of suicide has been estimated to be 10 times higher in those with 
epilepsy than in the general population.33  Furthermore, depression has been found to be 
the single strongest predictor of health-related quality of life in patients with epilepsy.34  
In a survey of the concerns of people with epilepsy, approximately 30% of people 
spontaneously reported depressed mood as a significant problem in living and dealing 
with epilepsy.35  Despite the obvious impact of depression in patients with epilepsy, it 
often remains unrecognized and untreated.  Reasons cited for this include the incorrect 
assumption on the part of clinicians and patients that mood disorders are to be expected 
with chronic health conditions, and the false beliefs that antidepressants are either 
ineffective or will exacerbate seizures in patients with epilepsy.20,36
 While the clinical presentation of depression in epilepsy can be identical to that of 
patients without epilepsy, it can also differ considerably.  Depression in patients with 
epilepsy can present as and major depression, bipolar disorder, dysthymic disorder, and 
minor depression20; a considerable number of cases fail to meet the clinical criteria of  the 
DSM-IV Axis I categories.  This is primarily due to the intermittent course of interictal 
depression, with symptomatic periods ranging from hours to days interrupted by 
symptom-free periods of similar duration.32  This discrepancy has recently lead Blumer et 
al to introduce the term “interictal depressive disorder” to describe the syndrome seen 
specifically in patients with epilepsy.37  The existence of a depressive disorder exclusive 
to patients with epilepsy, however, remains controversial.  It is still uncertain whether it 
represents a unique clinical syndrome or a simply a cluster of symptoms failing to fully 
meet the DSM-IV criteria for a depressive disorder.  This diagnostic labeling variability 
is part of the problem with using a categorical classification system such as the DSM-IV 
to identify depression in patients with epilepsy.38
In addition to the above factors, some theorize that a common neuropathogenic 
mechanism for both depression and epilepsy is the reason for their high rates of co-
morbidity.  Not only is the prevalence of depression high in patients with epilepsy, but a 
study in Sweden found that a history of depression was associated with a 4- to 6-fold 
greater risk of developing epilepsy.39  This has led to the suggestion that decreased 
serotonergic and noradrenergic function may be a common pathogenic mechanism for 
both depression and epilepsy.20  
   
Depression in Patients with Epilepsy Treated with VNS
To our knowledge only three studies (Harden et al.40, Elger et al.41 and Hoppe et 
al.42) have looked into the effects of VNS on the treatment of depressive symptoms in 
patients with epilepsy.  In 2000, Harden et al. used the Cornell Dysthymia Rating Scale, 
the Hamilton Depression Scale (HAM-D), the Hamilton Rating Scale for Anxiety and the 
Beck Depression Inventory (BDI) to assess changes in symptoms of depression in 20 
patients with epilepsy after 3 months of treatment with VNS as compared to a control 
group of 20 patients with epilepsy not treated with VNS.  They found a significant 
decrease in depression scale scores after three months the VNS group, however the scores 
at three months in the VNS group were not significantly different from those in the 
control group.  Interestingly, the study found no correlation between seizure frequency 
reduction and mood change.40   
The Elger et al. study used the Rating Scales for Psychiatry, the Brief Psychiatric 
Rating Scale, the Montgomery Asberg Depression Rating Scale, the Scale for the 
Assessment of Negative Symptoms and the Hypomania Scale to measure symptoms of 
depression at baseline, 4 weeks before VNS implantation, and 3-6 months after 
implantation in patients with epilepsy randomly assigned to either high- or low-
stimulation VNS.  In both groups they found significant improvement in scores on most 
scales (including the Brief Psychiatric Rating Scale, the Montgomery Asberg Depression 
rating scale, and the flattened affect, alogia, and abulia subsets of the Scale for the 
Assessment of Negative Symptoms), at 3 and 6 months as compared to baseline, with 
improvement being more pronounced in the high-stimulation group at the end of the 
study. 41  Again, this study found no correlation between seizure activity and mood 
changes. 
The study by Hoppe, et al. measured changes in symptoms of depression in 28 
patients with epilepsy treated with VNS for at least 6 months, using the Befindlischkeits-
Skala (a German mood adjective list), the Beck Depression Inventory, the Self-Rating on 
Anxiety Scale, and the Behavioral Psychosocial Scales on Epilepsy.  They found 
improvement in symptoms of tension and dysphoria, but not in symptoms of depression, 
level of activity, or health-related quality of life.    
The above studies have two major areas of concern.  First, all three measured 
changes in symptoms of depression after 3-6 months of VNS therapy, despite the fact that 
the literature shows that the efficacy of VNS in treating depression and epilepsy improves 
with longer duration of treatment.43,    44 Furthermore, these studies assessed changes in 
symptoms of depression with scales designed to gauge symptom severity in patients who 
have already received a clinical diagnosis of depression.  The Beck Depression Inventory 
is of primary clinical use, according to the American Pyschiatric Assocation, to “assess 
severity of depressive symptoms in patients with previously diagnosed depressive 
illness.”45  Similarly, the Hamilton Depression Scale has its main clinical utility as a 
“useful gauge of the degree of symptom severity in depressed cohorts.” 45  Finally, the 
Montogmery-Asberg Depression Rating scale is best used to “gauge the degree of 
symptom severity in depressed patients.” 
The CES-D is the only scale that “measures the degree of depressive symptoms in 
a community sample”, and has also been shown to be effective at identifying depression 
when compared to the “gold standard” of structured psychiatric interviews such as the 
Mini International Neuropsychiatric Interview (MINI) and the Structured Clinical 
Interview for DSM-IV Axis I Disorders (SCID-I).46  Thus, the CES-D seems to be a 
more appropriate scale for patients with epilpesy, as it may be better at identifying 
depressive symptoms consistent with the so-called interictal dysphoric/depressive 
disorder, but which fail to meet the criteria of Major Depressive Disorder.    
   
Methods
Design – This study was an un-blinded survey study of self-reported effects of VNS on 
symptoms of depression in patients with epilepsy.  Effects were assessed retrospectively, 
with a group of patients who have had VNS for 1 to 3 years rating their depressive 
symptoms before VNS and 1 year after. 
Inclusion Criteria- Participants had to 18 years of age or older and have epilepsy treated 
with VNS for one year or more.  Participants also had a level of cognition, as assessed by 
clinician who knew them well, that would allow them to complete self-survey forms 
independently or with slight assistance.     
Patients – Patients were recruited from the epilepsy clinic at UNM as well as from the 
Epilepsy Support Group.   
Measures – Patients were asked to complete two different self-report surveys, the Center 
for Epidemiology Studies – Depression Scale (CES-D) and the Dartmouth Primary Care 
Cooperative Information Functional Health Assessment Charts (COOP).  The COOP 
Charts was designed for everyday use in the clinical setting to quickly determine 
information about a patient’s health status.  It consists of 9 charts, each with a single 
question that refers to the status of health in the last 4 weeks.  All of the charts have a 
descriptive title, a single question, and 5-point response scale (1 represents no limitations 
and 5 represents severe limitation), with an illustration for each response.  Each chart 
assesses a different concept and is scored individually.   Overall the COOP Charts assess 
physical activity, emotional status, daily and social activities, pain, emotional support, 
and general health.47  The charts were used in our subjects to evaluate their functioning 
and see if it correlated with their depression scores.  This gave us another tool with which 
to further assess the validity of our retrospective method. 
The CES-D is a 20-item checklist that assesses the severity of depressive 
symptoms over a period of 4 weeks.  It is scored by summing items which are rated on a 
four-point scale corresponding to four different response phrases: “rarely or none of the 
time”, “some”, “occasionally”, or “most or all of the time”. Depressed subjects are 
defined as those who score 15 points or higher. 
In addition to these two scales, subjects were asked a series of questions about 
their epilepsy.  All subjects were asked what medications they are currently taking, the 
cause of their seizures (if known), how long they have had seizures, whether they have 
any past or present history of substance abuse, and if they have ever been hospitalized for 
seizures or drug toxicity.  Subjects were asked to determine their seizure frequency 
(defined as number per month) and to rate the severity of their seizures on a line scale 
(see attached).  Finally, subjects were asked why they got the implant, the date of 
implantation, and the “dose” of VNS (estimated by multiplying the percentage of VNS 
stimulation “on” time by the output current in mA).46
Time points for the measures - The retrospective group was asked to respond to one set of 
these scales and questions in reference to their memory of their mood and functioning for 
the month before they started VNS and to respond to another set of these scales and 
questions in regard to their mood and functioning after 1 year of VNS treatment.  
Statistical Analysis - A paired t-test was used to calculate the statistical significance of 
VNS at baseline and one year after treatment in our retrospective group.  The rationale 
for the use of the paired t-test was the desire to compare the mean before and after 
treatment of the same patients, and to look for a significant difference.   All statistical 
calculations were performed using Excel. 
Results 
After one year of recruitment at the VNS clinic and epilepsy support group we 
were able to recruit 7 patients in to our retrospective group, and were unable to recruit 
any patients in to our prospective group. 
Study Subject Demographics
 Six out of seven subjects listed uncontrollable seizures as the reason they were 
being treated with VNS.  One participant listed “depression from seizures” as their reason 
for getting the implant.  Duration of treatment with VNS ranged from 9-5 years, with an 
average of 5.75 year.  Two participants were actually on their second implant.  The doses 
of VNS (defined as the product of the percent of VNS “on” time and the output current in 
milliamps) ranged from 0.05 to 0.25, with the average being 0.16.  The average number 
of seizures per month reported by participants ranged from <1 to 30, with an average of 
8.1 seizures/month.  Participants reported taking 1 to 3 antiepleptic medications, with an 
average of 1.8.  The most common medications were Keppra (3 participants) and 
Lamictal (2 participants).  The number of years participants have had seizures ranged 
from 5 to 41 years, with an average of 19.3 seizures years. Participants listed a variety of 
etiologies for their epilepsy including: unknown, hereditary, history of high fever, and 
traumatic brain injury.   
   
CES-D 
The main scale that was used to evaluate depressive symptoms in our patient 
population was the Center for Epidemiologic Study of Depression scale.   The scoring 
system defines scores of 0 to 14 points as not depressed, 15 to 21 points as mild to 
moderate depression, and 22 or above as severe depression.  Depressed subjects are 
defined as those who score 15 points or higher.  The results are listed in table 1-1. 
Table 1-1, CES-D scores 1 month prior to VNS and at least 1 year after VNS insertion 
Subject # 1 mo prior to VNS insertion 1 year post VNS insertion 
845          12  (not depressed) 14  (not depressed) 
471          44  (severe depression) 19  (mild depression) 
248          38  (severe depression) 39  (severe depression) 
463          22  (severe depression) 22  (severe depression) 
542          29  (severe depression) 15  (mild depression) 
20          14   (not depressed) 13  (not depressed) 
827          11   (not depressed) 17  (mild depression) 
 
 Three of the seven subjects (43%) showed a drop in their CES-D score after one 
year of VNS insertion, and two of these subjects changed from a classification of 
severely depressed to mild to moderately depressed.  Three subjects (43%) actually 
showed an increase, one changing from a classification of not depressed, to a 
classification of mildly depressed.  One subject showed no change.  These results are 
shown in table 1-2. 
Table 1-2, Total change in CES-D score after 1 year of VNS 
Subject # Change after 1 year VNS 
845 +2 (none to none) 
471 -25(severe to mild) 
248 +1 (severe to severe) 
463 0 (severe to severe) 
542 -14 (severe to mild) 
20 -1 (none to none) 
827 +6 (none to mild) 
 
 The overall mean change was from a CES-D initial score of 24.3, one month prior 
to VNS insertion, to a final score of 19.8, at least one year after insertion.  This represents 
a total change of 4.42 points for the group as a whole.  After performing a paired T test 
on the group, the t value was determined to be 1.065, correlating to a p value of 0.327, 
indicating that these results are not significant.  Therefore, despite an average overall 
decrease in CES-D scores observed with our seven subjects, the group results remain 
insignificant.  For the individuals who had a 14 and 25 point changes (subjects 471, 542), 
the differences were clinically significant.  
 
COOP 
The Cooperative Information Functional Health Assessment Charts (COOP) was 
designed for everyday use in the clinical setting to quickly determine information about a 
patient’s health status.  Overall the COOP Charts assess physical activity, emotional 
status, daily and social activities, pain, emotional support, and general health 
Although the CES-D was the main scale for measurement, we also chose to include the 
COOP, to try and determine if the VNS was actually acting just on depression, or if by 
improving functioning and quality of life, depressive symptoms would improve.  Table 2-
1 shows the results of the COOP survey one month prior to VNS insertion, and at least 
one year after insertion. 
Table 2-1, COOP results 
Subject # 1 mo prior to VNS insertion 1 year post VNS insertion 
20 16 11 
248 27 28 
463 27 25 
542 30 20 
471 30 17 
827 31 21 
845 23 16 
 
 Six out of the seven subjects (86%) showed improvement, after VNS insertion, as 
demonstrated by a decrease in total score.  These results are listed in Table 2-2. 
Table 2-2, Total change in COOP scale after at least one year of VNS treatment 
Subject # Total Change 
20 -5 
248 +1 
463 -2 
542 -10 
471 -13 
827 -10 
845 -7 
  
 The average COOP score for the group one month before VNS implant was 29, 
dropping to 22.2 at least one year after VNS.  The change of 6.8, was significant, yielding 
a t value of 3.528, correlating to a p=0.012.   
  
Seizure Frequency Scale 
 In addition to the CES-D and COOP, we also had participants rate their seizure 
severity during the one month prior to VNS insertion, and at least one year after insertion.  
The scale was a line scale ranging from “no seizures” to “worst seizures you’ve ever 
had”.  The scale measured 10 cm in length, so that participant’s marks could be easily 
converted to a numerical value, ranging from 0-10.  Table 3-1 lists the results. 
Table 3-1, Seizure Severity Scale Results 
Subject # 1 mo prior to VNS 1 year after VNS 
845 Omitted omitted 
248 Omitted omitted 
471 6.7 2.5 
463 5 3.3 
542 8.4 4.7 
20 3.1 3.1 
827 10 1.3 
   
 Four out of the seven subjects (57%) showed decrease in seizure severity after at 
least one year of VNS, while one showed no change.  Two subjects did not fill out the 
scale.  The total change is reported in Table, 3-2.  
Table 3-2, Total change in seizure severity after at least one year of VNS insertion 
Subject # Change in seizure severity 
845 Omitted 
248 Omitted 
471 -4.2 
463 -1.7 
542 -3.7 
827 -8.7 
020 0 
 
 The average seizure severity among the group was 6.64 prior to VNS insertion, 
dropping to 2.98 after at least one year of VNS.  The represents a total change of 3.66, 
correlating to a p value of 0.06, which is approaching statistical significance.   
General Trends between Seizure Severity, Mood and Functioning 
 Although the number of subjects in our study was small, there did appear to be a 
few general trends observed among the group.   
Depression and Seizure Severity 
 Five out of seven subjects filled out scales on both depression (CES-D) and 
seizure severity after at least one year of VNS treatment.  Of those, two out of five (40%), 
had improvement of both mood and seizures.  One out of five, (20%), showed 
improvement in depression alone, with no change in seizure severity.  Another 
participant, (20%), showed improvement in seizures alone, with no change in symptoms 
of depression.  Lastly, one out of five, (20%), showed improvement in seizures with 
worsening depression. 
Table 4-1-Relationship between depression and seizure severity at least one year after 
VNS insertion 
-negative values=improvement                     -positive values=worsening 
Changes in depression and seizure severity after 
one year of VNS
-30
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-10
-5
0
5
10
1 2 3 4 5
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Seizure Severity
 
Functioning and Seizure Severity 
 Five out of seven individuals reported results on seizure severity and functioning 
(COOP).  In this case, four out of five (80%), showed an improvement in both seizure 
severity and functioning after at least one year of VNS treatment.  One subject had 
improvement in functioning only.   
Table 4-2, Relationship between functioning and seizure severity after at least one year of 
VNS treatment 
Changes in functioning and seizure severity at 
least one year after VNS
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Functioning and Depression 
 On the topic of the relationship of functioning and depression after one year of 
VNS treatment, four out of seven (57%), had a correlation between the two factors.  
Three of those four had improvement in both, and one individual had worsening of both.  
Two had improvement in functioning with no change in depression, and one had a 
worsening of depression despite improvement in functioning. 
Table 4-3, Relationship between functioning and depression after at least one year of 
VNS treatment 
Changes in functioning and depression at least 
one year after VNS treatment
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Discussion 
Our study sought to provide further understanding on how treatment with VNS 
alters symptoms of depression in patients with epilepsy.  We hoped to expand upon the 
current research in this area by using a different scale, one that may be appropriate than 
those used in previous studies for assessing symptoms of depression in patients with 
epilepsy.  Furthermore, we sought to assess changes in symptoms of depression after a 
longer period of treatment with VNS (1 year), as research suggests the efficacy of VNS in 
treating both seizures and depression improves over time periods of 1 year or more.  
Although our main scale for determining depressive symptoms in our population 
did show a small decrease of 4.42, this decrease did not have statistical significance.  This 
is likely due to the very small number of individuals we were able to recruit in to our 
study.  The two subjects that showed a clinically significant improvement in depression 
with changes of 14 and 25 on the CES-D, suggest that there may be a subset of strong 
responders to VNS as a treatment for depression.  Our results also suggest that if the 
study size could be larger, perhaps a more significant difference could be seen.  49    
Of interest is that the COOP showed statistically significant improvement after at 
least one year of VNS treatment.  It is hard to determine if these results suggest that the 
VNS is acting mainly on seizure control, thereby improving the quality of life, and in turn 
depressive symptoms, or if it is actually improving all three.  In our limited population 
we found more of a correlation between improvement in functioning and depression 
(57%), and functioning and seizure severity (80%), than depression and seizure severity 
(40%).  This would suggest, as studies by Harden40 and Elger41 have found, that a 
decrease in seizure severity is not directly related to the change in depression observed in 
patients treated with VNS.  Our results seem to indicate that a decrease in seizure severity 
relates more with an improvement in functioning, and thereby an improvement in 
depression. 
Change in seizure severity after one year of VNS approached statistical 
significance, with 4 out of the 5 participants who filled out the scales reporting a decrease 
in severity and the fifth reporting no change.  While this finding is encouraging in terms 
of the effectiveness of VNS, it makes it difficult to determine if the improvements in 
symptoms of depression and overall functioning were due to decreased seizures severity 
alone. 
As we had anticipated, we had difficulty in obtaining the number of individuals 
necessary to power our study.  The duration of one year for recruitment does not appear 
to be long enough, and the VNS clinic and epilepsy support group did not provide enough 
subjects.  Besides the fact that there are simply a limited number of patients with epilepsy 
treated with VNS, this population contains a significant portion of people with congenital 
neurological disorders.  Many of these disorders are associated with limited cognitive 
function, which may preclude participation in survey study such as this, which requires 
skills in reading comprehension and ability for personal insight. 
We had also intended to have a second group of individuals, with whom we could 
measure depressive symptoms using the CES-D scale before implant and then one year 
after, but were unable to recruit any subjects for this group.  This group would have 
provided valuable information about the reliability of our retrospective collection 
method.   
The design of the study was problematic in several ways.  The process of simply 
handing out packets of surveys in clinic and having the participants fill them out and 
return them in their own time likely limited the number of participants who completed the 
study.  Furthermore, the somewhat complicated nature of the survey packets, with two 
sets of surveys for before VNS and after, required detailed labeling of each page, which 
made it impossible to blind the scorers as to which scales were filled in reference to 
before and after VNS.   
Although this pilot study had areas that need improvement, our results do suggest 
that one year of treatment with VNS is improving symptoms of depression, and that the 
CES-D is a useful scale for measuring depressive symptoms in individuals with epilepsy.  
This study also seems to suggest that there may be a group of strong responders to VNS 
as a treatment for depression.  The initial aim of this study was to look mainly for 
changes in depressive symptoms, but this study also showed significant changes in 
overall functioning.  These changes in overall functioning appear to be strongly 
correlated with reduction in seizures and improvement in depression.   
We hope this project will be continued in the future, with a longer collection time 
and more expansive recruitment sites.  It would likely greatly improve patient willingness 
to participate and full completion of scales if they were filled out during an office visit 
with the help of a research assistant who would not be involved in the scoring process.  
This would also help with obtaining patients for a truly prospective arm of the study.  
Scales could be filled out during an intake process before implantation and repeated one 
year after implantation.  For all of these reasons, continuation of this project would be 
best implemented in a VNS clinic, with the completion of scales integrated into office 
visits.   
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